Navigation Links
Lilly Announces Termination of AIR Insulin Program

.90. See the reconciliation table below for further detail.

Reconciliation of 2008 Earnings Per Share Expectations:

2008 2007

Expectations Results % Growth

--------------- --------- ---------

E.P.S. (reported) $3.73 to $3.90 $2.71

Eliminate estimated charge

related to asset impairments

and certain wind-down costs

associated with the

termination of the AIR Insulin

program .05 to .07

Eliminate estimated in-process

research and development

charge associated with BioMS

Medical in-licensing .05

Eliminate asset impairments,

restructuring and other

special charges - .15

Eliminate charge for a

reduction in expected

insurance recoveries - .06

Eliminate in-process research

& development charges

associated with ICOS, Hypnion, - .63

and Ivy acquisitions and OSI,

MacroGenics and Glenmark in-

licensing transactions

Include pro forma as if the

ICOS acquisition was completed

on January 1, 2006 - (.01)

-------------- ---------

E.P.S. (pro forma adjusted) $3.85 to $4.00 $3.54 9% to 13%

-------------- ---------

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provi

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
(Date:10/8/2015)... ... , ... Talon Innovations, a provider of Precision Machined Products and ... is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the ... Innovations was recognized as a nominee for this competitive award. , The “Best ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... ... October 07, 2015 , ... The Riordan-McKenna ... a public educational seminar on the latest advances in adult stem cell therapy ... – 3:00 pm at the Hilton Dallas/Southlake Town Square in Southlake, Texas. , ...
(Date:10/7/2015)... 7, 2015   PDI , a leader in ... that highlights key challenges across various healthcare settings, as ... the situation. This tool is part of a larger ... to create efficiencies and lower healthcare-associated infections. ... emphasizes examples of how to use the right product, ...
Breaking Biology Technology:
... PALO ALTO, Calif., Oct. 22 Telik, Inc.,(Nasdaq: ... call and,webcast will be held on Wednesday, November 5, ... following the release earlier that day of the,company,s financial ... The conference call will be accessible via Telik,s ...
... SAN FRANCISCO, Oct. 22 Dynamic Alert Limited,(OTC ... biotechnology,leader specializing in the commercialization of medical cannabis-based,pharmaceutical ... it has,signed an agreement to acquire all of ... operated by Medical Cannabis pioneer and political,activist Steven ...
... continues to build for the company,s key technologies, ... Inc.,(OTC Bulletin Board: DSCI), a company specializing in ... focusing on its new,technologies have been accepted and ... Advances in Skin & Wound Care in Las ...
Cached Biology Technology:
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
(Date:9/24/2015)... , Sept. 24, 2015  EyeLock LLC, a market ... its award winning and latest technology in Booth #602 ... California . EyeLock,s iris authentication technology ... unmatched biometric accuracy, making it the most proven way ... uses video technology to deliver a fast and friendly ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
Breaking Biology News(10 mins):
... Mo. For years, researchers have known that high ... blood pressure causes blood vessels to relax. Until recently, ... the exact proteins responsible for this phenomenon. Now, using ... resolution - and isolating blood vessels outside the body, ...
... stress by producing significant amounts of a chemical form ... at the National Center for Atmospheric Research (NCAR), opens ... plants and their impacts on air quality, and it ... warning signal about crops that are failing. "Unlike ...
... may be no such thing as a ,safe, tan based ... published in the October issue of Pigment Cell & ... of Pigment Cell Societies (IFPCS) and the Society for Melanoma ... leading researchers in the fields of cell biology, dermatology and ...
Cached Biology News:
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
... low background ,This solution greatly enhances antigen-antibody ... than obtained with conventional methods. ,Two kinds ... secondary antibodies, which can suppress the background ... Wide versatility ,It is applicable to various ...
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Biology Products: